36.3 Acute Liver Injury & Viral Hepatitis

Biochemical Patterns of Liver Injury & The R-Value Framework

Abnormal liver biochemistries are frequently encountered in primary care. To avoid diagnostic confusion, the clinician must distinguish between tests reflecting hepatocyte integrity (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), tests reflecting cholestasis and biliary secretion (alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT], and bilirubin), and tests reflecting true hepatic synthetic function (prothrombin time / international normalized ratio [PT/INR] and serum albumin).

The R-Value Formulation & Classification

The initial branching point in evaluating acute liver injury is determining whether the primary injury is hepatocellular, cholestatic, or mixed, quantified using the R-value (also known as the alanine aminotransferase to alkaline phosphatase ratio):

$\text{R-Value} = \frac{\text{Serum ALT} / \text{Upper Limit of Normal (ULN) for ALT}}{\text{Serum ALP} / \text{Upper Limit of Normal (ULN) for ALP}}$

1. Hepatocellular Pattern (R >= 5.0):
   • Characterized by marked, disproportionate elevation of ALT and AST relative to ALP.
   • Reflects primary hepatocyte necrosis, inflammation, or membrane leakage.
2. Cholestatic Pattern (R <= 2.0):
   • Characterized by disproportionate elevation of ALP (and GGT) relative to ALT/AST.
   • Reflects impaired bile formation, canalicular transport defects, or mechanical biliary obstruction.
3. Mixed Pattern (R between 2.0 and 5.0):
   • Concurrent hepatocyte necrosis and canalicular epithelial injury; common in drug-induced liver injury (DILI).

Differential Diagnosis of Extreme Transaminitis (>1,000 to >5,000 U/L)

While mild transaminitis (<300–500 U/L) has a broad differential (NAFLD, chronic viral hepatitis, alcohol, celiac disease, medications), massive transaminitis exceeding 1,000 U/L (and often reaching 2,000 to 10,000+ U/L) narrows the differential diagnosis to five major conditions:

1. Ischemic Hepatitis ('Shock Liver'):
   • Precipitated by transient profound systemic hypotension, cardiac arrest, cardiogenic shock, severe sepsis, or severe hypoxemia.
   • Features an abrupt, explosive rise in AST and ALT (often >3,000–5,000 U/L) accompanied by an extraordinarily high serum Lactate Dehydrogenase (LDH) level (LDH:ALT ratio typically >1.5).
   • Followed by an equally rapid, dramatic fall in transaminases (50% reduction every 24 to 72 hours) once hemodynamic stability is restored.
2. Toxin- & Acetaminophen (APAP)-Induced Hepatotoxicity:
   • Intentional or accidental acetaminophen overdose, Amanita phalloides (death cap mushroom) poisoning, carbon tetrachloride, or herbal supplements (kava, germander).
3. Acute Viral Hepatitis:
   • Acute Hepatitis A, acute Hepatitis B, acute Hepatitis E, and rarely acute Hepatitis C, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), or Herpes Simplex Virus (HSV) hepatitis.
4. Acute Autoimmune Hepatitis (AIH):
   • Severe acute presentation characterized by marked hypergammaglobulinemia (elevated IgG) and positive autoantibodies (Antinuclear Antibodies [ANA], Anti-Smooth Muscle Antibodies [ASMA], or Anti-Liver Kidney Microsome 1 [anti-LKM1]).
5. Acute Budd-Chiari Syndrome:
   • Acute thrombosis of the hepatic veins or inferior vena cava, causing severe sinusoidal congestion, ischemic centrilobular necrosis, painful hepatomegaly, and new-onset ascites.

The De Ritis Ratio (AST:ALT Ratio)

• In Most Acute Hepatocellular Injuries (Viral Hepatitis, Ischemia, DILI):
  • ALT is greater than AST (AST:ALT ratio < 1.0). ALT is localized exclusively in the hepatocyte cytoplasm and has a substantially longer serum half-life (~47 hours) than AST (~17 hours).
• In Alcohol-Induced Liver Disease (Alcoholic Hepatitis):
  • AST:ALT Ratio >= 2.0 (with AST typically <300–500 U/L).
  • Pathophysiologic Mechanisms:
    1. Alcohol is a direct mitochondrial toxin, causing selective mitochondrial membrane rupture and releasing mitochondrial AST (mAST).
    2. Chronic alcohol consumption induces severe hepatic deficiency of pyridoxal 5'-phosphate (vitamin B6). Vitamin B6 is an obligatory coenzyme for both AST and ALT enzymatic synthesis, but ALT synthesis is far more sensitive to B6 depletion, severely blunting the liver's ability to produce and release ALT.
  • High-Yield Board Pearl: Serum transaminases in pure alcoholic hepatitis rarely exceed 500 U/L. If a heavy drinker presents with an AST or ALT >500 to 1,000 U/L, do NOT attribute it solely to alcohol; immediately investigate for superimposed acetaminophen toxicity, ischemic hepatitis, or viral hepatitis!

Cholestatic Pattern: Alkaline Phosphatase & GGT Evaluation

• Confirming Hepatic Origin: Alkaline phosphatase is produced by hepatocytes, bone osteoblasts, the placenta (in pregnancy), and the ileal mucosa. Elevated ALP must be confirmed as hepatic in origin by checking Gamma-Glutamyl Transferase (GGT) or 5'-nucleotidase. GGT is NOT elevated in bone disorders.
• Imaging Workup: Transabdominal ultrasound is the mandatory first step to evaluate for intrahepatic versus extrahepatic ductal dilatation:
  • Ductal Dilatation Present: Extrahepatic mechanical obstruction (choledocholithiasis, pancreatic head adenocarcinoma, cholangiocarcinoma).
  • Ductal Dilatation Absent: Intrahepatic cholestasis:
    1. Primary Biliary Cholangitis (PBC): Autoimmune destruction of interlobular bile ducts in middle-aged women; positive Anti-Mitochondrial Antibodies (AMA), elevated IgM, fatigue, pruritus; treated with oral ursodeoxycholic acid (UDCA).
    2. Primary Sclerosing Cholangitis (PSC): Fibro-obliterative destruction of intra- and extrahepatic bile ducts; 'beaded' appearance on MRCP; strongly associated with Ulcerative Colitis (in 70-80%); positive p-ANCA.
    3. Drug-Induced Cholestasis: Amoxicillin-clavulanate is the single most common cause of idiosyncratic drug-induced cholestatic liver injury in clinical practice (often appearing 2 to 6 weeks after completing therapy); other culprits include anabolic steroids, oral contraceptives, erythromycin, and chlorpromazine.

---

Evaluating Hepatic Synthetic Function & Acute Liver Failure (ALF)

True Hepatic Synthetic Function Markers

Transaminases (AST, ALT) measure cell death, not organ function. The liver can lose 80% of its parenchyma while transaminases drop to normal as hepatocytes burn out.

• Prothrombin Time / International Normalized Ratio (PT/INR):
  • The earliest and most sensitive indicator of acute hepatic synthetic failure!
  • The liver synthesizes all coagulation factors except Factor VIII (produced by endothelial cells). Factor VII has the shortest biological half-life of any clotting factor (only 4 to 6 hours).
  • A sudden decline in hepatic synthetic function depletes circulating Factor VII within hours, rapidly prolonging the PT and elevating the INR.
• Serum Albumin:
  • Albumin is synthesized exclusively by the liver, but has a long serum half-life of approximately 20 days.
  • Consequently, in acute liver injury, acute viral hepatitis, or acetaminophen poisoning, serum albumin remains completely normal! Hypoalbuminemia reflects chronic liver disease (cirrhosis), nephrotic syndrome, severe protein malnutrition, or protein-losing enteropathy.

Clinical Definition & Staging of Acute Liver Failure (ALF)

Acute Liver Failure (historically termed fulminant hepatic failure) is a catastrophic medical emergency defined by the simultaneous presence of three criteria:

1. Severe Acute Liver Injury (massive transaminitis and hyperbilirubinemia);
2. Coagulopathy with an INR >= 1.5;
3. Hepatic Encephalopathy (altered mental status, confusion, asterixis, stupor, or coma);

• Occurring in a patient WITHOUT pre-existing cirrhosis with an illness duration of less than 26 weeks.

                      ACUTE LIVER FAILURE TEMPORAL SUBTYPES

     [Hyperacute: <7 Days] ───────> APAP Overdose, Ischemic Hepatitis, HAV
                                   • Explosive transaminitis, rapid onset encephalopathy
                                   • High risk of cerebral edema; good transplant-free recovery

     [Acute: 7 to 21 Days] ───────> Acute Hepatitis B Infection
                                   • Moderate cerebral edema risk; intermediate prognosis

     [Subacute: 4 to 26 Weeks] ───> Idiosyncratic DILI, Autoimmune Hepatitis
                                   • Insidious jaundice, low transaminases, late encephalopathy
                                   • Low cerebral edema risk; exceptionally POOR survival (<20%)
                                     without emergency liver transplantation

Critical Management Principles in Acute Liver Failure

• Immediate Transfer to a Liver Transplant Center ICU: Delay in transfer is the leading cause of preventable death in ALF.
• Cerebral Edema & Intracranial Hypertension (Leading Cause of Death in ALF):
  • Severe hyperammonemia (>150-200 mcmol/L) results in excessive glutamine accumulation inside cerebral astrocytes, driving osmotic swelling, cerebral edema, intracranial hypertension, and fatal brainstem herniation.
  • Management: Elevate head of bed 30 degrees; maintain serum sodium at 145 to 150 mEq/L with 3% hypertonic saline; administer IV mannitol (0.5–1.0 g/kg) for acute intracranial pressure (ICP) spikes; avoid hypercapnia and hypoxemia.
• Metabolic Derangements: Check point-of-care blood glucose hourly; profound hypoglycemia occurs rapidly due to impaired gluconeogenesis and depleted glycogen stores; requires continuous IV 10% or 20% dextrose infusion.
• Infection Prophylaxis: Broad-spectrum empiric IV antibiotics and antifungals; loss of hepatic reticuloendothelial clearance causes overwhelming bacteremia and fungemia.
• N-Acetylcysteine (NAC) in Non-Acetaminophen ALF: Intravenous NAC has been proven to improve systemic hemodynamics, tissue microvascular perfusion, and transplant-free survival in early-stage non-acetaminophen ALF.
• King's College Criteria for Emergency Liver Transplantation:
  • Acetaminophen ALF: Arterial pH <7.30 after fluid resuscitation, OR all three of: INR >6.5, serum creatinine >3.4 mg/dL, and Grade III/IV encephalopathy.
  • Non-Acetaminophen ALF: INR >6.5, OR any three of: etiology (idiosyncratic DILI, indeterminate), age <10 or >40 years, jaundice-to-encephalopathy interval >7 days, INR >3.5, serum bilirubin >17.5 mg/dL.

---

Acetaminophen (APAP) Hepatotoxicity & Management Protocols

Acetaminophen toxicity is the single most common cause of acute liver failure in the Western world, responsible for nearly 50% of all ALF cases in the United States.

Molecular Pathophysiology of APAP Hepatotoxicity

• Normal Metabolism (Therapeutic Doses <=4 g/day): 85% to 90% is safely conjugated via hepatic glucuronidation and sulfation into harmless, water-soluble metabolites excreted in urine.
• Toxic Intermediate Generation: Approximately 5% to 10% is metabolized by cytochrome P450 enzymes (predominantly CYP2E1) into the highly reactive, electrophilic, toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
• Glutathione Detoxification: Under normal conditions, intracellular glutathione immediately conjugates NAPQI into non-toxic mercapturic acid and cysteine compounds.
• Overdose Cascade (>7.5 to 10 g in adults, or >150 mg/kg): Primary glucuronidation and sulfation pathways become saturated, shunting massive amounts of APAP through CYP2E1. Once hepatic glutathione stores are depleted by >70%, free unneutralized NAPQI covalently binds to sulfhydryl groups on hepatocyte mitochondrial proteins. This triggers mitochondrial oxidative stress, loss of ATP production, mitochondrial permeability transition, and extensive centrilobular (Zone 3) hepatic necrosis (the zone of highest CYP2E1 expression and lowest oxygenation).
• Potentiating Factors: Chronic alcohol use (induces CYP2E1 and depletes glutathione), malnutrition/fasting (depletes glutathione), and CYP2E1 inducers (phenytoin, carbamazepine, isoniazid).

The Four Clinical Phases of Acetaminophen Poisoning

1. Phase 1 (0 to 24 Hours): Asymptomatic or non-specific mild nausea, vomiting, malaise, diaphoresis. Serum transaminases and bilirubin are completely normal.
2. Phase 2 (24 to 72 Hours) - 'The Latent Period': Nausea improves, but subclinical hepatotoxicity begins: rising AST and ALT, RUQ abdominal pain, hepatomegaly, rising PT/INR, and acute kidney injury (from direct toxic tubular necrosis).
3. Phase 3 (72 to 96 Hours) - Peak Hepatotoxicity: Fulminant hepatic necrosis: severe jaundice, massive transaminitis (AST and ALT frequently exceed 10,000 to 20,000 U/L), severe coagulopathy (INR >5 to 10), profound lactic acidosis, hypoglycemia, acute renal failure, and Stage III/IV hepatic encephalopathy.
4. Phase 4 (4 Days to 2 Weeks) - Recovery or Death: Complete hepatic regeneration over several weeks (without chronic fibrosis) in survivors, or death from multi-organ failure and cerebral edema.

The Rumack-Matthew Nomogram

• Strictly validated ONLY for a single, acute ingestion of known timing presenting between 4 and 24 hours post-ingestion.
• Cannot be used for chronic supratherapeutic ingestions, staggered doses, extended-release formulations, or ingestions presenting >24 hours later.
• Timing Rule: A serum APAP level drawn before 4 hours post-ingestion cannot be interpreted, because gastrointestinal drug absorption is incomplete. The 4-hour serum level must be plotted on the nomogram.
• Treatment Line: The treatment line begins at 150 mcg/mL (993 mcmol/L) at 4 hours post-ingestion and extends to 18.75 mcg/mL at 16 hours (incorporating a 25% safety buffer below the original 200 mcg/mL toxicity line). Any concentration on or above this 150 mcg/mL line mandates full antidote therapy.

Antidote Protocol: N-Acetylcysteine (NAC)

• Mechanism of Action: NAC serves as a precursor for glutathione synthesis (providing cysteine) and directly binds and detoxifies NAPQI as a glutathione surrogate. In late presentations, NAC also acts as an antioxidant and microcirculatory vasodilator.
• Efficacy Timing: NAC is most effective when administered within 8 hours of acute ingestion (reducing severe hepatotoxicity and mortality to near zero).
• Crucial Clinical Rule: However, NAC MUST STILL BE ADMINISTERED AT ANY TIME if the patient presents >8 hours post-ingestion with an APAP level above the nomogram line, or if the patient presents late (>24 hours) with elevated transaminases or detectable APAP!
• Treatment Regimens:
  • Intravenous (IV) NAC (21-Hour Protocol):
    1. Loading dose: 150 mg/kg IV in 200 mL D5W over 60 minutes;
    2. Second dose: 50 mg/kg IV in 500 mL D5W over 4 hours;
    3. Third dose: 100 mg/kg IV in 1,000 mL D5W over 16 hours.
    • Adverse Effect: Anaphylactoid Reaction (non-IgE-mediated histamine release causing flushing, urticaria, angioedema, or bronchospasm in up to 10-15% of patients, typically during the initial high-concentration loading dose). Management: temporarily stop infusion, administer IV diphenhydramine (and epinephrine if bronchospasm/shock), and resume the infusion at a slower rate once symptoms resolve.
  • Oral NAC (72-Hour Protocol):
    • Loading dose: 140 mg/kg orally; followed by 70 mg/kg orally every 4 hours for 17 maintenance doses (total 72 hours). Pre-treat with antiemetics (ondansetron).
• Stopping Criteria: NAC must NOT be discontinued blindly at 21 or 72 hours. Continue NAC until: 1) Serum APAP is undetectable; 2) AST and ALT are normal or clearly declining substantially; and 3) INR is <1.5 and renal function is stable.

---

Acute Viral Hepatitis Spectrum: Serologies & Management

Hepatitis A Virus (HAV)

• Virology & Transmission: Non-enveloped RNA picornavirus transmitted via the fecal-oral route through contaminated food or water, raw shellfish, international travel to endemic nations, daycare exposure, or sexual contact (MSM). Incubation period: 15 to 50 days (mean 28 days).
• Clinical Features: Acute, self-limited febrile illness with jaundice, dark urine (bilirubinuria), acholic stools, and RUQ tenderness. Children <6 years are typically anicteric (70%), whereas adults are symptomatic with jaundice (>70%).
• Chronicity & Complications: HAV NEVER causes chronic hepatitis, cirrhosis, or hepatocellular carcinoma! Fulminant liver failure occurs in <0.5% (higher in older adults or underlying liver disease).
• Serologic Interpretation:
  • Anti-HAV IgM: Positive at symptom onset, peaks during acute phase, and persists for 3 to 6 months. Confirms acute Hepatitis A infection.
  • Anti-HAV IgG: Appears soon after IgM and persists for life. Confirms past natural infection or vaccination, conferring lifelong immunity.
• Post-Exposure Prophylaxis (PEP): Must be administered within 14 days of exposure:
  • Healthy individuals aged 12 months to 40 years: Single dose of Hepatitis A vaccine.
  • Infants <12 months, adults >40 years, immunocompromised, or chronic liver disease: Hepatitis A Immune Globulin (IG, 0.1 mL/kg) (or vaccine + IG in high-risk individuals >40 years).

Hepatitis B Virus (HBV)

• Virology & Transmission: Partially double-stranded circular DNA hepadnavirus transmitted parenterally (percutaneous blood contact, needle sharing), sexually, or perinatally (vertical transmission). Incubation period: 45 to 160 days (mean 90 days).
• Age-Dependent Risk of Chronicity (Critical Board Concept):
  • Neonates (Perinatal Transmission): 90% develop chronic Hepatitis B infection (due to immune tolerance).
  • Children aged 1 to 5 years: 20% to 30% develop chronic HBV.
  • Immunocompetent Adults: Less than 5% develop chronic infection (>95% clear the virus and develop protective immunity).
• Serologic Markers & Clinical Interpretation:
  • HBsAg (Surface Antigen): First marker to appear. Indicates active infection (acute or chronic if persistent >6 months).
  • Anti-HBs (Surface Antibody): Neutralizing antibody. Denotes immunity and viral clearance (titer >=10 mIU/mL from natural infection or vaccination).
  • Anti-HBc IgM (Core Antibody IgM): Hallmark of acute Hepatitis B infection! Present during acute illness and persists for 4 to 6 months.
    • The 'Window Period': Interval between the disappearance of HBsAg and the appearance of detectable Anti-HBs. During this window, Anti-HBc IgM is the SOLE positive serologic marker of recent acute infection!
  • Anti-HBc IgG (Total Core Antibody): Appears during acute infection and persists for life. Positive in anyone who experienced natural infection; NEGATIVE in individuals immune via vaccination!
  • HBeAg (Envelope Antigen): Marker of active, high viral replication and high infectivity.
  • Anti-HBe: Seroconversion denotes transition to lower replication.
  • HBV DNA: Quantitative viral load by PCR.

Comprehensive Hepatitis B Serology Matrix

• Management of Acute HBV: Supportive care in >95% of immunocompetent adults. Oral nucleos(t)ide analogues (entecavir or tenofovir disoproxil fumarate / TAF) are indicated ONLY for severe/fulminant acute HBV (coagulopathy INR >=1.5, severe protracted jaundice >4 weeks, or acute liver failure).
• Post-Exposure Prophylaxis (PEP): Following percutaneous or mucosal exposure to an HBsAg-positive source:
  • Unvaccinated individual: Administer Hepatitis B Immune Globulin (HBIG) PLUS the first dose of the Hepatitis B vaccine series within 24 hours.
  • Previously vaccinated individual with documented anti-HBs >=10 mIU/mL: No prophylaxis or treatment required (patient is fully immune).

Hepatitis C Virus (HCV)

• Virology & Transmission: Enveloped single-stranded RNA flavivirus transmitted primarily through blood (injection drug use, unsterilized tattoos, transfusions before 1992). Incubation period: 2 to 26 weeks.
• Natural History: Acute HCV is asymptomatic in 70% to 80% of cases. Spontaneous clearance occurs in only 15% to 25% of individuals; 75% to 85% develop chronic Hepatitis C infection, which slowly progresses over decades to cirrhosis (in 20%) and hepatocellular carcinoma.
• Diagnostic Testing Algorithm:
  • Screen with Anti-HCV antibody. If positive, reflex immediately to quantitative HCV RNA PCR.
  • Positive Anti-HCV + Positive HCV RNA = Active HCV Infection (acute or chronic).
  • Positive Anti-HCV + Negative HCV RNA = Resolved past infection or successfully cured HCV.
• Management of Acute HCV: Monitor quantitative HCV RNA PCR for 12 to 16 weeks following diagnosis to allow for spontaneous clearance. If HCV RNA remains detectable after 12 to 16 weeks, initiate pan-genotypic Direct-Acting Antivirals (glecaprevir-pibrentasvir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks), achieving cure rates (SVR) >95% to 98%.

Hepatitis D Virus (HDV, 'Delta Agent')

• Defective circular RNA virus that is obligate dependent on Hepatitis B virus: requires HBsAg to synthesize its viral envelope coat. It cannot infect in the absence of HBV.
• Modes of Infection:
  1. Coinfection: Simultaneous acquisition of HBV and HDV. Causes severe acute hepatitis, but chronicity is low (<5%, matching HBV clearance in adults).
  2. Superinfection: Acute HDV infection acquired by a chronic HBsAg carrier. Triggers severe acute decompensation and carries a catastrophic 70% to 80% rate of rapid progression to cirrhosis and liver failure.
• Prevention: Hepatitis B vaccination completely prevents Hepatitis D infection!

Hepatitis E Virus (HEV)

• Non-enveloped RNA hepevirus. Genotypes 1 and 2 are transmitted enterically via the fecal-oral route through contaminated drinking water in developing nations (large epidemics in South/East Asia and Africa). Genotypes 3 and 4 are zoonotic in developed nations, transmitted via undercooked pork, wild boar, or deer meat.
• Usually causes an acute, self-limited hepatitis similar to HAV with zero progression to chronicity in immunocompetent hosts.

• [!CAUTION] CRITICAL BOARD EXAM PEARL: CATASTROPHIC HEV MORTALITY IN PREGNANCY In pregnant women—particularly during the third trimester—acute Hepatitis E infection (specifically Genotypes 1 and 2) carries an extraordinary and alarming 15% to 25% mortality rate due to rapidly progressive fulminant hepatic failure, obstetric hemorrhage, and eclampsia. Any pregnant woman returning from an endemic developing region (e.g., South Asia) presenting with acute severe jaundice, acute liver failure, and negative HAV, HBV, and HCV serologies has acute Hepatitis E infection until proven otherwise!